Nitric oxide (SB 206)

Drug Profile

Nitric oxide (SB 206)

Alternative Names: NVN-1000 SB-206; SB-206

Latest Information Update: 27 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novan Inc
  • Class Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antifungals; Antihypertensives; Antivirals; Free radicals; Macromolecular substances; Nitrogen oxides; Non-opioid analgesics; Small molecules; Vasodilators
  • Mechanism of Action Androgen receptor antagonists; Angiogenesis inducing agents; Cell death stimulants; Nitric oxide donors; Reactive oxygen species modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Genital warts; Human papillomavirus infections
  • Discontinued Staphylococcal infections

Most Recent Events

  • 20 Mar 2017 Novan completes a phase II trial in Genital warts in USA (NCT02462187; 9213297)
  • 29 Nov 2016 Novan plans pivotal phase III trial for Genital warts in USA
  • 29 Nov 2016 Efficacy and adverse events data from a phase II trial in Genital warts released by Novan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top